AbbVie Acquires Celsius Therapeutics for $250 Million, Expanding Inflammatory Disease Portfolio
AbbVie, Celsius Therapeutics, Acquisition, Inflammatory Diseases, M&A, Biotech
Daiichi Sankyo Secures $47 Million Victory in ADC Patent Arbitration Against AstraZeneca
Daiichi Sankyo, AstraZeneca, ADC Patent Arbitration, $47 Million Settlement
Ginkgo Bioworks to Lay Off Up to 400 Employees Amid Cost-Cutting Measures
Ginkgo Bioworks, layoffs, cost-cutting, biosecurity, cell programming, workforce reduction
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
Lykos Faces Setback as ICER Concludes Insufficient Evidence for MDMA-Based PTSD Treatment
Lykos Therapeutics, MDMA, PTSD, ICER, Insufficient Evidence, Clinical Trials, FDA Approval
FDA Rejects Merck-Daiichi Sankyo’s Lung Cancer Drug, Approves New Treatments for COPD and Lymphoma
FDA, Merck, Daiichi Sankyo, NSCLC, COPD, Lymphoma, Patritumab Deruxtecan, Ensifentrine, Epkinly
FDA Approves EPKINLY (Epcoritamab-Bysp) for Relapsed or Refractory Follicular Lymphoma
EPKINLY, epcoritamab-bysp, follicular lymphoma, FDA approval, relapsed or refractory, bispecific antibody, T-cell engaging, subcutaneous treatment
Arc Institute Unveils Revolutionary Bridge Editing Technology for Programmable Genome Design
Bridge editing, genome design, programmable gene editor, DNA strands, Arc Institute, CRISPR, RNA-guided systems, genetic engineering
US Supreme Court Rejects Purdue’s Multibillion-Dollar Opioid Pact
US Supreme Court, Purdue Pharma, Opioid Settlement, Sackler Family, Bankruptcy, Opioid Crisis
EU Calls for Cooperation and Increased Manufacturing to Overcome GLP-1 Shortage
GLP-1 receptor agonists, EU, shortages, diabetes, weight management, manufacturing, cooperation, regulatory actions